Skip to content
RUO · Research Use Only⚠ IGF-1 Elevation✓ Free to read

CJC-1295

A growth-hormone shot whose maker quietly shut the whole program down in 2008, after a death in a related trial.

Updated 19 May 2026Read 4 minBacked by 30 studies
The quick version
What it is
A shot that raises growth hormone and IGF-1
Is it FDA-approved?
No. Sold through clinics or for research only
How strong is the proof?
Weak: just one small human study, back in 2006
How you take it
A small shot under the skin
Typical result
Higher IGF-1 (a growth signal) for days at a time
Biggest catch
A long-term growth signal that may feed cancer; banned in sports

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

CJC-1295 is a medicine you inject. It does not give you growth hormone directly. Instead, it tells your own body to make more.

Your body makes a hormone called growth hormone. CJC-1295 copies a natural signal that turns that hormone on. This kind of helper is called a . When growth hormone goes up, another growth signal called goes up too.

There are two versions, and they are not the same. CJC-1295 with DAC stays in your body about 8 days, so people take it once a week. CJC-1295 without DAC (often labeled "Mod GRF 1-29") clears in under 30 minutes, so people take it several times a week. If the label does not say which one it is, you do not know what you are really taking.

It is not . That means the U.S. government has not checked it and agreed it is safe and that it works.

What people use it for.

People use CJC-1295 to raise growth hormone. They hope for better sleep, more muscle, faster recovery, and an anti-aging boost.

Most often it does not come alone. Clinics usually mix it with another called ipamorelin. That pair is the most common growth-hormone combo clinics prescribe. If your clinic sold you "GH peptide therapy," this mix is likely what is in the vial.

Does it actually work?

We honestly do not know much. The human proof is very thin.

There is only one real human study, from 2006. It showed that CJC-1295 does raise growth hormone and . But it never tested whether that helps you in real life. There are zero larger trials that looked at things like muscle, fat, or aging.

The company that was developing it stopped its program in 2008 after a death in a related trial. It never started again. So the "more muscle, better sleep, younger you" story is mostly word of mouth, not proof.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

The CJC and ipamorelin stack gives you better sleep, more muscle, and an anti-aging boost.

unproven

The one human study, from 2006, only showed CJC raises growth hormone. It never tested whether that does anything for muscle, fat, or aging. The rest is word of mouth.

It's safer than real HGH because your own body makes the hormone.

not quite

It still pushes to 1.5 to 3 times your normal level, and IGF-1 is the same growth signal tumors use to grow. Nobody has studied what years of that does to a person.

Clinics prescribe it, so it must be proven.

half true

Hormone clinics do sell the CJC plus ipamorelin combo, but it is , not , and the whole prescription leans on that single 20-year-old study.

It's fine for athletes since it isn't a steroid.

no

WADA bans it at all times. In any tested sport this is an automatic fail, steroid or not.

How you take it.

You take it as a small shot under the skin. This kind of shot is called a shot. People usually inject the belly or the thigh.

How often depends on the version. The with-DAC version lasts about 8 days, so people dose it once a week. The no-DAC version clears in under 30 minutes, so people dose it 5 to 7 times a week.

A common goal is to raise to about 1.5 to 3 times your normal level. That is a lot, and it is the part that worries us.

What to watch out for.

The serious stuff

  • is a growth signal. Tumors are unwanted growth. A long-term growth signal could in theory feed cancer. Do not use this if you have or recently had cancer.
  • Nobody has studied what years of this does to you. There is no long-term safety data at all.
  • If your vial mixes CJC with ipamorelin, both raise . The risk adds up. Check both, not just one.

The common stuff

People report water retention, tingling in the hands, and feeling tired or flushed after a dose. These are common with growth-hormone helpers in general.

One more thing: it is banned in tested sports. WADA bans it at all times. If you compete, this is an automatic no.

If anything feels wrong, talk to a real doctor. We are not your doctor.

Where people get it.

Here are the ways people get it, from safest to riskiest.

  • Brand. There is none. No CJC-1295 exists.
  • . Made by special pharmacies, usually through a hormone clinic. This is the most common and lowest-risk path. It runs about $150 to $495 a month, often bundled with ipamorelin.
  • Research-only (). Sold "for research only," about $25 to $60 a month. Cheap, but no promise of what is in the vial. You mix it yourself.
  • . Unregulated imports, about $5 to $20 a month. Same molecule as , even cheaper, even riskier.

One thing to watch: the label must say "with DAC" or "no-DAC." Those are different drugs with very different timing. If the seller cannot tell you which one it is, walk away. Ask for a , a lab report that shows what is really in the vial.

Our honest take.

Mostly no
We would not run CJC-1295 as a healthy adult. The whole pitch rests on one small study from 20 years ago, and the growth signal it raises is the same kind of signal cancer uses to grow.

If a real hormone doctor diagnosed you with adult growth-hormone deficiency, that is different. Even then we would ask about real HGH first, then maybe the no-DAC version. We would never pick the with-DAC version, because it keeps that growth signal high for days.

If you do run it anyway, keep checking your with bloodwork. Stop the moment it climbs above the normal range for your age.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism. 2006;91(3):799-805. PMID: 16352683.
  2. 02Van Hout MC, et al. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse. 2016;51(1):73-84. PMID: 26771670.
  3. 03Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026;10(1). PMID: 41490200.
  4. 04Timms M, et al. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug testing and analysis. 2019;11(8):1248-1257. PMID: 30938069.
  5. 05Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. 2026;54(1):223-229. PMID: 41476424.
  6. 06Timms M, et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug testing and analysis. 2019;11(6):804-812. PMID: 30489688.
  7. 07Henninge J, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis. 2010;2(11-12):647-50. PMID: 21204297.
  8. 08Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism. 2006;291(6):E1290-4. PMID: 16822960.
  9. 09Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug testing and analysis. 2021;13(11-12):1871-1887. PMID: 34665524.
  10. 10Ionescu M, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism. 2006;91(12):4792-7. PMID: 17018654.
  11. 11Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. PMID: 15817669.
  12. 12Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2009;19(6):471-7. PMID: 19386527.
  13. 13Cristea CD, et al. Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples. Analytical biochemistry. 2023;682:115336. PMID: 37806509.
  14. 14Thomas A, et al. Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls. Methods (San Diego, Calif.). 2012;56(2):230-5. PMID: 21871962.
  15. 15Thomas A, et al. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. Journal of mass spectrometry : JMS. 2024;59(1):e4996. PMID: 38197510.
  16. 16Thomas A, et al. Probing for peptidic drugs (2-10 kDa) in doping control blood samples. Analytical science advances. 2022;3(7-8):235-243. PMID: 38716080.
  17. 17Knoop A, et al. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and bioanalytical chemistry. 2016;408(12):3145-53. PMID: 26879649.
  18. 18Danila GM, et al. Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor. Talanta. 2022;237:122905. PMID: 34736642.
  19. 19Renke G, et al. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. International journal of molecular sciences. 2026;27(9). PMID: 42123471.
  20. 20Thevis M, et al. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert review of proteomics. 2014;11(6):663-73. PMID: 25382550.
  21. 21Coppieters G, et al. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. Journal of pharmaceutical and biomedical analysis. 2022;214:114726. PMID: 35298973.
  22. 22Thomas A, et al. Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. Drug testing and analysis. 2015;7(11-12):990-8. PMID: 26382721.
  23. 23Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in aging. 2026;7:1790247. PMID: 42021992.
  24. 24Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639.
  25. 25Pineau T, et al. The study of doping market: How to produce intelligence from Internet forums. Forensic science international. 2016;268:103-115. PMID: 27710891.
  26. 26Gautam D, et al. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(15):6398-403. PMID: 19332789.
  27. 27Pont L, et al. Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. Journal of chromatography. A. 2020;1631:461548. PMID: 32971474.
  28. 28Kwok WH, et al. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Analytical and bioanalytical chemistry. 2013;405(8):2595-606. PMID: 23318763.
  29. 29Uçaktürk E, et al. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2026;268:117207. PMID: 41138283.
  30. 30Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. 2026. PMID: 41880199.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.